Fenbendazole (also known as Fenben or Panacur) is an anthelmintic of the benzimidazole class. The medicine was first used in 1974 and is now used all around the world. It is inexpensive to make and widely available in many nations.

Over the last several decades, it has been shown that fenbendazole and similar drugs have a measurable anti-cancer impact. Several studies have shown that anthelmintic medicines alone can cause tumor regression in a variety of tumor forms; however, they can also be used in conjunction with other traditional therapy approaches.

These findings sparked conjecture that fenbendazole may be repurposed as a supplementary anti-cancer medication. Surprisingly, benzimidazole class medications appear to function in the same way as a large range of contemporary chemotherapeutic agents, such as taxols and vinca alkaloids, but without the high toxicity.

According to the existing toxicological data, fenbendazole appears to be well tolerated in people following oral administration and has minimal adverse effects. However, human observations are restricted.

http://www.mhsvbrstudy.com/2020/01/14/fenbendazole-dosage-guide/

Under normal settings, pure fenbendazole appears as a yellowish powder with a low water solubility. When the chemical is dissolved in acetone, it emits colored impurities above itself.

After oral treatment, fenbendazole has poor intestinal absorption. When taken, no more than 10% of the drug is absorbed.

The presence of food in the intestines can boost bioavailability. Food slows the intestines and boosts blood flow to the digestive tract, which improves medicine absorption.

http://www.mhsvbrstudy.com/2020/01/12/fenbendazole-protocol/